BR112015019568A2 - Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo - Google Patents
Peptídeo isolado, composição compreendendo o mesmo e uso do mesmoInfo
- Publication number
- BR112015019568A2 BR112015019568A2 BR112015019568A BR112015019568A BR112015019568A2 BR 112015019568 A2 BR112015019568 A2 BR 112015019568A2 BR 112015019568 A BR112015019568 A BR 112015019568A BR 112015019568 A BR112015019568 A BR 112015019568A BR 112015019568 A2 BR112015019568 A2 BR 112015019568A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- peptide
- mpkekvflkiekmgrnirn
- amino acid
- acid residues
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010056340 Diabetic ulcer Diseases 0.000 abstract 1
- 108700022013 Insecta cecropin B Proteins 0.000 abstract 1
- 206010072170 Skin wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001617 migratory effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Birds (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764913P | 2013-02-14 | 2013-02-14 | |
| PCT/US2014/012378 WO2014126681A1 (en) | 2013-02-14 | 2014-01-21 | Short bio-active peptides for promoting wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015019568A2 true BR112015019568A2 (pt) | 2017-08-22 |
Family
ID=50069319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015019568A BR112015019568A2 (pt) | 2013-02-14 | 2014-01-21 | Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9487558B2 (enExample) |
| EP (1) | EP2956155B1 (enExample) |
| JP (1) | JP6348126B2 (enExample) |
| KR (1) | KR101894829B1 (enExample) |
| CN (1) | CN105120884B (enExample) |
| AR (1) | AR094835A1 (enExample) |
| AU (1) | AU2014216730B2 (enExample) |
| BR (1) | BR112015019568A2 (enExample) |
| CA (1) | CA2898717C (enExample) |
| CY (1) | CY1119087T1 (enExample) |
| DK (1) | DK2956155T3 (enExample) |
| ES (1) | ES2633437T3 (enExample) |
| HU (1) | HUE033976T2 (enExample) |
| MX (1) | MX363955B (enExample) |
| MY (1) | MY173174A (enExample) |
| NZ (1) | NZ711281A (enExample) |
| PL (1) | PL2956155T3 (enExample) |
| RU (1) | RU2606753C1 (enExample) |
| SG (1) | SG11201505538QA (enExample) |
| SI (1) | SI2956155T1 (enExample) |
| TW (1) | TWI587867B (enExample) |
| WO (1) | WO2014126681A1 (enExample) |
| ZA (1) | ZA201505516B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019519596A (ja) * | 2016-04-08 | 2019-07-11 | コーネル・ユニバーシティーCornell University | シルク由来タンパク質を使用して創傷治癒を増進する方法 |
| EP3312608B1 (en) * | 2016-10-24 | 2019-10-02 | Akribes Biomedical GmbH | Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound |
| US10232009B1 (en) * | 2017-09-29 | 2019-03-19 | Pro Sunfun Biotech Research And Development Co., Ltd. | Peptide for promoting wound healing, its composition and method of using the same |
| CN108586575B (zh) * | 2018-04-11 | 2020-08-14 | 福建省中科生物股份有限公司 | 一种多肽及其皮肤修复功能的应用 |
| CZ308845B6 (cs) * | 2019-01-21 | 2021-07-07 | Globetech Innovation S.R.O | Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran |
| CN116407611A (zh) * | 2021-12-29 | 2023-07-11 | 四川好医生攀西药业有限责任公司 | 一种多肽在制备预防或治疗皮肤损伤疾病产品上的应用 |
| WO2025215346A1 (en) * | 2024-04-08 | 2025-10-16 | The Boots Company Plc | Skin wound treatment |
| WO2025215347A1 (en) * | 2024-04-08 | 2025-10-16 | The Boots Company Plc | Skin wound treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6360939A (ja) * | 1986-08-29 | 1988-03-17 | Shin Etsu Chem Co Ltd | 抗菌物質 |
| DE3854476T2 (de) | 1987-07-06 | 1996-04-04 | Univ Louisiana State | Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden. |
| US5861478A (en) | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
| EP3002294B8 (en) * | 2006-06-13 | 2018-05-16 | Helix Biomedix Inc. | Peptide fragments for inducing synthesis of extracellular matrix proteins |
| RU2458069C2 (ru) * | 2007-01-05 | 2012-08-10 | Хеликс Байомедикс Инк. | Выделенный пептид для усиления ранозаживляющей активности кератиноцитов, композиция для заживления ран у млекопитающего и лекарственное средство для применения при заживлении ран у млекопитающего |
| RU2447896C1 (ru) * | 2010-11-15 | 2012-04-20 | Общество с ограниченной ответственностью "Аллофарм" | Антимикробное вещество |
| CA3203271A1 (en) * | 2011-08-25 | 2013-02-28 | University Of Central Florida Research Foundation, Inc. | Methods and compositions comprising a c-terminal bax peptide |
-
2014
- 2014-01-21 ES ES14703220.5T patent/ES2633437T3/es active Active
- 2014-01-21 MX MX2015009404A patent/MX363955B/es active IP Right Grant
- 2014-01-21 SI SI201430277T patent/SI2956155T1/sl unknown
- 2014-01-21 RU RU2015138925A patent/RU2606753C1/ru not_active IP Right Cessation
- 2014-01-21 CN CN201480009001.0A patent/CN105120884B/zh active Active
- 2014-01-21 CA CA2898717A patent/CA2898717C/en active Active
- 2014-01-21 MY MYPI2015702327A patent/MY173174A/en unknown
- 2014-01-21 EP EP14703220.5A patent/EP2956155B1/en active Active
- 2014-01-21 HU HUE14703220A patent/HUE033976T2/en unknown
- 2014-01-21 SG SG11201505538QA patent/SG11201505538QA/en unknown
- 2014-01-21 JP JP2015558016A patent/JP6348126B2/ja active Active
- 2014-01-21 NZ NZ711281A patent/NZ711281A/en not_active IP Right Cessation
- 2014-01-21 DK DK14703220.5T patent/DK2956155T3/en active
- 2014-01-21 AU AU2014216730A patent/AU2014216730B2/en not_active Ceased
- 2014-01-21 KR KR1020157024070A patent/KR101894829B1/ko not_active Expired - Fee Related
- 2014-01-21 US US14/762,407 patent/US9487558B2/en active Active
- 2014-01-21 BR BR112015019568A patent/BR112015019568A2/pt not_active Application Discontinuation
- 2014-01-21 WO PCT/US2014/012378 patent/WO2014126681A1/en not_active Ceased
- 2014-01-21 PL PL14703220T patent/PL2956155T3/pl unknown
- 2014-01-29 TW TW103103686A patent/TWI587867B/zh not_active IP Right Cessation
- 2014-02-14 AR ARP140100481A patent/AR094835A1/es unknown
-
2015
- 2015-07-31 ZA ZA2015/05516A patent/ZA201505516B/en unknown
-
2016
- 2016-09-20 US US15/270,186 patent/US20170000848A1/en not_active Abandoned
-
2017
- 2017-07-14 CY CY20171100747T patent/CY1119087T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI587867B (zh) | 2017-06-21 |
| MX363955B (es) | 2019-04-08 |
| CA2898717C (en) | 2019-01-08 |
| KR101894829B1 (ko) | 2018-09-05 |
| MX2015009404A (es) | 2016-10-07 |
| WO2014126681A1 (en) | 2014-08-21 |
| ZA201505516B (en) | 2016-10-26 |
| CY1119087T1 (el) | 2018-01-10 |
| EP2956155B1 (en) | 2017-04-19 |
| CA2898717A1 (en) | 2014-08-21 |
| ES2633437T3 (es) | 2017-09-21 |
| SG11201505538QA (en) | 2015-08-28 |
| DK2956155T3 (en) | 2017-07-31 |
| NZ711281A (en) | 2017-12-22 |
| US20170000848A1 (en) | 2017-01-05 |
| JP2016513107A (ja) | 2016-05-12 |
| AU2014216730A1 (en) | 2015-08-20 |
| JP6348126B2 (ja) | 2018-06-27 |
| HK1212243A1 (en) | 2016-06-10 |
| US20150353605A1 (en) | 2015-12-10 |
| MY173174A (en) | 2020-01-02 |
| RU2606753C1 (ru) | 2017-01-10 |
| AR094835A1 (es) | 2015-09-02 |
| SI2956155T1 (sl) | 2017-10-30 |
| AU2014216730B2 (en) | 2015-12-17 |
| HUE033976T2 (en) | 2018-02-28 |
| TW201446258A (zh) | 2014-12-16 |
| US9487558B2 (en) | 2016-11-08 |
| CN105120884A (zh) | 2015-12-02 |
| KR20150116883A (ko) | 2015-10-16 |
| CN105120884B (zh) | 2017-08-29 |
| EP2956155A1 (en) | 2015-12-23 |
| PL2956155T3 (pl) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015019568A2 (pt) | Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| BR112019008975A2 (pt) | variantes de superfície celular imunologicamente discerníveis para uso em terapia celular | |
| BR112014016672A2 (pt) | compostos de carbamato e sua preparação e uso | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
| BR112013010844A2 (pt) | nova endolisina | |
| BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
| WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
| BR112017023380A2 (pt) | sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo. | |
| BR112015006828A8 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 | |
| BR112012027055A2 (pt) | agente estabilizante para proteínas farmacêuticas. | |
| BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
| UY33802A (es) | Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja | |
| BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| MX391136B (es) | FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO | |
| WO2017200659A3 (en) | A method to enhance wound healing using silk-derived protein | |
| NZ751231A (en) | Silk-derived protein for treating inflammation | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
| BR112022003745A2 (pt) | Proteínas de fusão terapêuticas | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: HELIX BIOMEDIX INC. (US) |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |